Titre
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Thoueille, P.
Auteure/Auteur
Alves Saldanha, S.
Auteure/Auteur
Schaller, F.
Auteure/Auteur
Munting, A.
Auteure/Auteur
Cavassini, M.
Auteure/Auteur
Braun, D.
Auteure/Auteur
Günthard, H.F.
Auteure/Auteur
Kusejko, K.
Auteure/Auteur
Surial, B.
Auteure/Auteur
Furrer, H.
Auteure/Auteur
Rauch, A.
Auteure/Auteur
Ustero, P.
Auteure/Auteur
Calmy, A.
Auteure/Auteur
Stoeckle, M.
Auteure/Auteur
Battegay, M.
Auteure/Auteur
Marzolini, C.
Auteure/Auteur
Andre, P.
Auteure/Auteur
Guidi, M.
Auteure/Auteur
Buclin, T.
Auteure/Auteur
Decosterd, L.A.
Auteure/Auteur
On Behalf Of The Swiss Hiv Cohort Study, -
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1999-4923
Statut éditorial
Publié
Date de publication
2022-07-29
Volume
14
Numéro
8
Première page
1588
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
SHCS#879 is an ongoing Switzerland-wide multicenter observational study conducted within the Swiss HIV Cohort Study (SHCS) for the prospective follow-up of people living with HIV (PLWH) receiving long-acting injectable cabotegravir-rilpivirine (LAI-CAB/RPV). All adults under LAI-CAB/RPV and part of SHCS are enrolled in the project. The study addresses an integrated strategy of treatment monitoring outside the stringent frame of controlled clinical trials, based on relevant patient characteristics, clinical factors, potential drug-drug interactions, and measurement of circulating blood concentrations. So far, 91 blood samples from 46 PLWH have been collected. Most individuals are less than 50 years old, with relatively few comorbidities and comedications. The observed concentrations are globally in accordance with the available values reported in the randomized clinical trials. Yet, low RPV concentrations not exceeding twice the reported protein-adjusted 90% inhibitory concentration have been observed. Data available at present confirm a considerable between-patient variability overall. Based on the growing amount of PK data accumulated during this ongoing study, population pharmacokinetic analysis will characterize individual concentration-time profiles of LAI-CAB/RPV along with their variability in a real-life setting and their association with treatment response and tolerability, thus bringing key data for therapeutic monitoring and precision dosage adjustment of this novel long-acting therapy.
PID Serval
serval:BIB_EA4A25E4F31E
PMID
Open Access
Oui
Date de création
2022-08-15T11:55:32.447Z
Date de création dans IRIS
2025-05-20T22:56:54Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
pharmaceutics-14-01588-v2 (4).pdf
Version du manuscrit
published
Licence
https://creativecommons.org/licenses/by/4.0
Taille
1.14 MB
Format
Adobe PDF
PID Serval
serval:BIB_EA4A25E4F31E.P001
URN
urn:nbn:ch:serval-BIB_EA4A25E4F31E0
Somme de contrôle
(MD5):0d65e058c6857a4d225a4b2865e086f9